Do DCTs Still Offer Clinical Precision in Challenging Patient Populations?

Date Published:

On February 28, Signant’s Clinical Vice President David Miller and Senior Director of Analytics Jan Breemans sat down with Oracle Health Sciences to discuss how to assure clinical precision in decentralized trials (DCT) with challenging patients. The speakers shared considerations for measurement precision when administering remote assessments, and discussed evolving regulatory guidance that may impact DCT conduct. They also shared patient-centric approaches to remote trial activities and ways to assure effective clinical oversight and data quality monitoring. 

You will also learn about the patient-empathetic strategies and solutions used to overcome technology literacy issues in a remote Alzheimer’s disease trial during COVID-19.

Tune into these expert insights and watch the webinar recording below.